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After publication of the original article [1] the authors
have noticed that some of the P-values were incorrect at
time of publication. This correction article is to show
the incorrect & correct values and to explain how this
affects the original publication.
For Fig. 1, Table 3 and supplementary file 1 only the
correct information is available via this correction
article.
 Abstract
Correct: The number of annual antibiotic
courses (− 0.7 courses, p = 0.04) was significantly
reduced in the anti-IL5/IL5R group, and total
number of exacerbation events were reduced in
both groups (− 4.4 events/year, p < 0.05 in the
anti-IL5/IL5R group and − 1.5events/year, p < 0.05
in the anti-IgE group).
Incorrect: The number of annual antibiotic
courses (− 0.7 courses, p = 0.04) and total number
of exacerbation events (− 4.4 events/year, p < 0.05)
were reduced in the anti-IL5/IL5R group.
 Results
Correct: The reduction in total exacerbation
events was statistically significant in the anti-IgE
group (from 4.7/year to 3.2/year, p = 0.006)
Incorrect: The reduction in total exacerbation
events was not statistically significant in the anti-
IgE group (from 4.7/year to 3.2/year, p = 0.229)
 Discussion
Correct: This study suggests that anti-IL5/
IL5R and anti-IgE therapies reduce per oral gluco-
corticoid use and total exacerbations.
Incorrect: This study suggests that anti-IL5/
IL5R therapy reduces exacerbations and anti-IL5/
IL5R and anti-IgE therapies reduce per oral gluco-
corticoid use.
Correct: Results of this study are otherwise in
concordance with previous studies, except from
the lack of statistical significance in the reduction
of the daily OCS dose with omalizumab.
Incorrect: Results of this study are otherwise
in concordance with previous studies, except from
the lack of statistical significance in the reduction
of the daily OCS dose and total annual
exacerbation events with omalizumab.
 Conclusions
Correct: In this retrospective real-life study,
biologicals reduced OCS courses and total
exacerbation events, and CRS-surgery rate in
patients with co-morbid CRS.
Incorrect: In this retrospective real-life study,
biologicals reduced OCS courses in both groups
and reduced total exacerbation events in the anti-
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
The original article can be found online at https://doi.org/10.1186/s40733-
020-00055-9.
* Correspondence: emma.kotisalmi@gmail.com
1Respiratory Diseases and Allergology, University of Helsinki and Helsinki
University Hospital, Inflammation Center, Meilahdentie 2, FI-00029 HUS, P.O.
Box 160, Helsinki, Finland
2Respiratory Diseases and Allergology, University of Helsinki and Helsinki
University Hospital, Heart and Lung Center, Helsinki, Finland
Full list of author information is available at the end of the article
Kotisalmi et al. Asthma Research and Practice            (2020) 6:10 
https://doi.org/10.1186/s40733-020-00063-9
IL5/IL5R group, and CRS-surgery rate in patients
with co-morbid CRS.
The total number of exacerbation events was statisti-
cally significantly reduced in both anti-IL5/IL5R and
anti-IgE groups. The reduction of the number of sick
leaves was significant in patients receiving anti-IL5/IL5R
therapy, but not in patients receiving anti-IgE therapy.
The improvement of lung function measured by FEV1
was not significant in either of the therapy groups.
Fig. 1 The corrected P-value is shown for All exacerbation events in Anti-IgE therapy
Table 3 corrected P-values for Sick leaves, Total number of exacerbation events and Mean FEV1 (litres)
Anti-IL5/IL5R (reslizumab,
mepolizumab, benralizumab)
N = 42 Anti-IgE
(omalizumab)
N = 22
Baseline Change P Baseline Change P
Sick leaves ** 0.93 (0–6. SD 1.72) −0.58 (−6–6. SD
1.86)
0.037 0.59 (0–4. SD 1.03) −0.14 (−3–11. SD
1.18)
0.602
Total number of exacerbation
events ***
7.57 (1–26. SD 5.59) −4.43 (−22–13. SD
6.24)
4.79
e− 05
4.68 (0–11. SD 3.40) −1.50 (− 7–21. SD
5.55)
0.006
Mean FEV1 (litres) 2.27 (1.0–4.2. SD 0.78) 0.17 (− 0.5–1.3. SD
0.41)
0.317 2.83 (1.5–4.2. SD
0.86)
0.05 (− 0.6–1.3. SD
0.54)
0.720
** Number due to asthma during the last 12months
*** defined as the sum of courses of oral glucocorticoid and antimicrobial drugs, sick leaves, hospitalisations and emergency room visits due to asthma during the
last 12months
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In this retrospective real-life study, biologicals reduced
OCS courses in both groups and reduced total number
of exacerbation events in both the anti-IL5/IL5R group
and in the anti-IgE group. After the correction our con-
clusions remain: biological therapy reduces exacerba-
tions and per oral corticosteroid use.
Supplementary information
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